Trials / Completed
CompletedNCT01962571
Treatment of Optic Neuritis With Erythropoietin: a Randomised, Double-blind, Placebo-controlled Trial
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 108 (actual)
- Sponsor
- University Eye Hospital, Freiburg · Academic / Other
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
This clinical trial aims at preventing visual dysfunction and optic nerve degeneration associated with autoimmune optic neuritis by systemic i.v. administration of 33.000 IU erythropoietin over 3 days. The primary objective is to determine the efficacy of erythropoietin compared to placebo given as add-on to methylprednisolone as assessed by measurements of retinal nerve fibre layer thickness and low contrast visual acuity 6 months after acute optic neuritis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Erythropoietin alfa | |
| DRUG | Placebo |
Timeline
- Start date
- 2014-11-25
- Primary completion
- 2018-06-20
- Completion
- 2019-11-26
- First posted
- 2013-10-14
- Last updated
- 2019-12-02
Locations
11 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT01962571. Inclusion in this directory is not an endorsement.